PGDx 获得 FDA 重新批准泛实体瘤液体活检的上市 FDA已授予PGDx elio plasma focus Dx pan实体瘤液体活检试验全新上市授权,用于通过简单抽血进行肿瘤突变分析。PGDx elio plasma focus DX是第一个也是唯一一个成套的泛实体肿瘤液体活检测试。基于定性下一代测序的体外诊断使用基于靶向高通量杂交的方法来捕获33个基因中...
PGDx applied the CE mark to its elio plasma resolve liquid biopsy test, which like elio tissue complete is intended to detect SNVs, indels, amplifications, rearrangements, and MSI, but uses targeted high throughput, parallel